Revolution Medicines, Inc. (RVMD) SEC Filings

Revolution Medicines, Inc. (RVMD) received a notice under Rule 144 that officer Anthony Mancini plans to sell common stock through Morgan Stanley Smith Barney. The notice covers up to 15,448 shares of common stock, with an aggregate market value of $3,208,240.64, in a transaction expected on September 10, 2026.

Revolution Medicines, Inc. (RVMD) director Lorence H. Kim reported the indirect sale of a total of 56,000 shares of Common Stock on August 31, 2026 through the Lorence Kim Revocable Trust in multiple open‑market transactions at prices around $200–$206 per share. The filing also shows 1,191 restricted stock units held directly and states that these sales were made under a Rule 10b5-1 trading plan adopted by the trust on June 1, 2026.

Revolution Medicines, Inc. (RVMD) entered into four long-term office and lab leases for new headquarters space totaling approximately 672,000 rentable square feet at 1600–1900 Seaport Boulevard in Redwood City, California. The leases have staggered commencement dates from September 26, 2027 through September 1, 2028, each with initial terms running to September 2042 and three optional five-year extensions at fair market rent.

At full commencement, aggregate scheduled monthly base rent is approximately $2.7 million, increasing about 3% annually, with rent-abatement periods through January 2030 providing about $23.1 million of base rent abatement. Landlords will provide tenant improvement allowances of about $115.9 million, and RVMD may elect up to an additional $40.3 million, amortized over the initial terms at 10% annually as additional rent. Effectiveness of the leases depends on a related property acquisition (the “Phase II Closing”), with specified rent reductions or termination rights if that closing is delayed or does not occur. Funds managed by Farallon Capital Management, L.L.C., which reported 6.4% beneficial ownership of RVMD common stock as of June 30, 2026, indirectly own a majority interest in the landlords.

Revolution Medicines, Inc. (RVMD) is the issuer of common stock that an affiliate, the Kim Revocable Trust (with Lorence H. Kim as trustee), has filed to sell under Rule 144. The planned sale covers 73,090 shares of common stock through J.P. Morgan Securities LLC, listed on Nasdaq. These shares were acquired by a 50,000-share open‑market purchase on July 20, 2022 and by restricted stock unit (RSU) vesting in several tranches totaling 23,090 shares between December 15, 2022 and June 26, 2026. The notice states that RVMD had 214,336,418 shares outstanding as of August 31, 2026, providing context for the size of the planned sale relative to total shares.

Revolution Medicines, Inc. (RVMD) announced that on August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

The approval is based on the global, randomized Phase 3 RASolute 302 trial comparing RASONQUE with investigator’s choice of cytotoxic chemotherapy in previously treated metastatic pancreatic adenocarcinoma. Once-daily oral RASONQUE tablets are now available in the United States, with a wholesale acquisition cost of $39,800 for a 30-day supply at the recommended daily dose.

Revolution Medicines, Inc. (RVMD) reported that its General Counsel, Jeff Cislini, exercised stock options and sold common shares on August 21, 2026 under a Rule 10b5-1 trading plan adopted on May 22, 2026. He exercised options for 56,280 shares of common stock at exercise prices of $18.56 and $21.61 per share and sold an aggregate of 56,894 shares of common stock in multiple trades at weighted average prices ranging from about $206.76 to $212.74 per share. Cislini’s holdings include 43,514 restricted stock units that remain outstanding.

Revolution Medicines, Inc. (RVMD) reported that President and Chief Executive Officer Mark A. Goldsmith exercised options for 80,000 shares of common stock at an exercise price of $4.73 per share and, on the same date, sold an aggregate of 86,000 shares of common stock in multiple transactions at weighted average prices between $206.78 and $212.74, including sales through revocable trusts. The filing notes that these transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026, and that his reported holdings include 182,938 restricted stock units.

Revolution Medicines, Inc. (symbol RVMD) received a notice that The Jonathan Goldsmith Revocable Trust, with Mark A. Goldsmith signing as trustee, has filed to sell shares of the company under Rule 144. The trust plans to sell 3,000 shares of common stock that were originally acquired as Founders Shares on 11/25/2014. The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with a stated aggregate market value of about $635,205.00 tied to 214,336,418 shares referenced in the form.

The filing also reports that during the past three months, 10,020 shares of Revolution Medicines common stock were sold on 06/16/2026 for total proceeds of approximately $1,564,310.38. The notice is signed and dated, indicating an intention to rely on Rule 144’s resale provisions for these securities.

Revolution Medicines, Inc. (symbol RVMD) received a Rule 144 notice that The Rebecca Goldsmith Revocable Trust intends to sell up to 3,000 shares of its common stock through Morgan Stanley Smith Barney LLC. The shares are described as Founders Shares acquired from the issuer on 11/25/2014.

The proposed sale relates to common stock listed on NASDAQ, with an indicated aggregate market value of approximately $635,205.00. The filing also notes that 214,336,418 shares of common stock were outstanding as of 08/21/2026. In the past three months, Mark A. Goldsmith sold 10,020 common shares on 06/16/2026 for about $1,564,310.38, and he signed the notice as trustee for the trust.